230 related articles for article (PubMed ID: 14981514)
1. Bystander elimination of antigen loss variants in established tumors.
Spiotto MT; Rowley DA; Schreiber H
Nat Med; 2004 Mar; 10(3):294-8. PubMed ID: 14981514
[TBL] [Abstract][Full Text] [Related]
2. Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells.
Spiotto MT; Schreiber H
Cancer Immun; 2005 Jun; 5():8. PubMed ID: 15934727
[TBL] [Abstract][Full Text] [Related]
3. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
4. IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers.
Zhang B; Karrison T; Rowley DA; Schreiber H
J Clin Invest; 2008 Apr; 118(4):1398-404. PubMed ID: 18317595
[TBL] [Abstract][Full Text] [Related]
5. IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice.
Song K; Chang Y; Prud'homme GJ
Gene Ther; 2000 Sep; 7(18):1527-35. PubMed ID: 11021590
[TBL] [Abstract][Full Text] [Related]
6. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
Sanchez-Perez L; Kottke T; Diaz RM; Ahmed A; Thompson J; Chong H; Melcher A; Holmen S; Daniels G; Vile RG
Cancer Res; 2005 Mar; 65(5):2009-17. PubMed ID: 15753401
[TBL] [Abstract][Full Text] [Related]
7. Molecular requirements for CD8-mediated rejection of a MUC1-expressing pancreatic carcinoma: implications for tumor vaccines.
Sivinski CL; Kohlgraf KG; VanLith ML; Morikane K; Tempero RM; Hollingsworth MA
Cancer Immunol Immunother; 2002 Aug; 51(6):327-40. PubMed ID: 12111121
[TBL] [Abstract][Full Text] [Related]
8. Tumors with reduced expression of a cytotoxic T lymphocyte recognized antigen lack immunogenicity but retain sensitivity to lysis by cytotoxic T lymphocytes.
Koeppen H; Acena M; Drolet A; Rowley DA; Schreiber H
Eur J Immunol; 1993 Nov; 23(11):2770-6. PubMed ID: 8223853
[TBL] [Abstract][Full Text] [Related]
9. Two types of anti-TL (thymus leukemia) CTL clones with distinct target specificities: differences in cytotoxic mechanisms and accessory molecule requirements.
Tsujimura K; Takahashi T; Iwase S; Matsudaira Y; Kaneko Y; Yagita H; Obata Y
J Immunol; 1998 Jun; 160(11):5253-61. PubMed ID: 9605121
[TBL] [Abstract][Full Text] [Related]
10. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
Winter H; Hu HM; Urba WJ; Fox BA
J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
[TBL] [Abstract][Full Text] [Related]
11. Antigenic cancer cells that escape immune destruction are stimulated by host cells.
Seung LP; Seung SK; Schreiber H
Cancer Res; 1995 Nov; 55(21):5094-100. PubMed ID: 7585557
[TBL] [Abstract][Full Text] [Related]
12. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.
Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
Blood; 2002 Nov; 100(9):3155-63. PubMed ID: 12384413
[TBL] [Abstract][Full Text] [Related]
13. The in vivo fate of APCs displaying minor H antigen and/or MHC differences is regulated by CTLs specific for immunodominant class I-associated epitopes.
Loyer V; Fontaine P; Pion S; Hétu F; Roy DC; Perreault C
J Immunol; 1999 Dec; 163(12):6462-7. PubMed ID: 10586037
[TBL] [Abstract][Full Text] [Related]
14. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells.
Zhang B; Bowerman NA; Salama JK; Schmidt H; Spiotto MT; Schietinger A; Yu P; Fu YX; Weichselbaum RR; Rowley DA; Kranz DM; Schreiber H
J Exp Med; 2007 Jan; 204(1):49-55. PubMed ID: 17210731
[TBL] [Abstract][Full Text] [Related]
15. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants.
van Hall T; Wolpert EZ; van Veelen P; Laban S; van der Veer M; Roseboom M; Bres S; Grufman P; de Ru A; Meiring H; de Jong A; Franken K; Teixeira A; Valentijn R; Drijfhout JW; Koning F; Camps M; Ossendorp F; Kärre K; Ljunggren HG; Melief CJ; Offringa R
Nat Med; 2006 Apr; 12(4):417-24. PubMed ID: 16550190
[TBL] [Abstract][Full Text] [Related]
16. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus.
Kreuwel HT; Morgan DJ; Krahl T; Ko A; Sarvetnick N; Sherman LA
J Immunol; 1999 Oct; 163(8):4335-41. PubMed ID: 10510373
[TBL] [Abstract][Full Text] [Related]
17. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
[TBL] [Abstract][Full Text] [Related]
18. Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance.
Ward PL; Koeppen HK; Hurteau T; Rowley DA; Schreiber H
Cancer Res; 1990 Jul; 50(13):3851-8. PubMed ID: 2112981
[TBL] [Abstract][Full Text] [Related]
19. High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.
Vierboom MP; Zwaveling S; Bos GMJ ; Ooms M; Krietemeijer GM; Melief CJ; Offringa R
Cancer Res; 2000 Oct; 60(19):5508-13. PubMed ID: 11034095
[TBL] [Abstract][Full Text] [Related]
20. Perforin-dependent elimination of dendritic cells regulates the expansion of antigen-specific CD8+ T cells in vivo.
Yang J; Huck SP; McHugh RS; Hermans IF; Ronchese F
Proc Natl Acad Sci U S A; 2006 Jan; 103(1):147-52. PubMed ID: 16373503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
